{"id":44885,"date":"2023-04-27T08:00:00","date_gmt":"2023-04-27T06:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-interim-report-q1-2023\/"},"modified":"2024-02-23T11:53:46","modified_gmt":"2024-02-23T10:53:46","slug":"stille-ab-interim-report-q1-2023","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-interim-report-q1-2023\/","title":{"rendered":"Stille AB: Interim Report Q1 2023"},"content":{"rendered":"
Stille AB (publ) publishes the report for the first quarter of the business year 2023. \u201dGood start \u2013 strong sales growth and significantly improved operating cashflow\u201d, summarizes President and CEO Torbj\u00f6rn Sk\u00f6ld.<\/strong><\/div>\n

Revenues increased in the first quarter by 17.5 percent to 72.4 (61.6) after strong growth from both business units. \u201cI am satisfied to see such strong growth compared to previous year given that the first quarter last year was a record quarter\u201d<\/em>, comments Torbj\u00f6rn Sk\u00f6ld.<\/span><\/p>\n

The gross profit amounted to 42.4 percent (44.8). Business unit Surgical Tables was affected by an unfavorable product and market mix, while Surgical Instruments was positively affected by the same factors. Operating profit, before one-time costs, amounted to 10.4 MSEK (7.6).<\/span><\/p>\n

\u201dStille\u2019s strategic and financial goals remain. With our high-quality products within surgical instruments and radiolucent surgical tables, we will operate in niche premium segments. 2023 has started well for Stille. We continue to deliver value to our customers, which creates good demand, strong growth and good cashflow\u201d<\/em>, concludes Stille\u2019s CEO.<\/span><\/p>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n
MSEK<\/span><\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\nJAN-MAR
\n\t\t\t2023<\/span><\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\n		JAN-MAR
\n\t\t\t2022<\/span><\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\n		APR-MAR
\n\t\t\t2022\/2023<\/span><\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\n		JAN-DEC
\n\t\t\t2022<\/span><\/span><\/strong><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Revenue<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n72.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n61.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n257.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n246.3<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Gross Profit Margin, %<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n42.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n44.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n42.9<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n45.3<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
EBITDA, before one-time costs<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n13.7<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n9.9<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n46.0<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n42.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
EBITDA <\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n10.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n9.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n42.7<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n42.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Operating Profit, before one-time costs<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n10.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n7.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n35.3<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n32.5<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Operating Profit<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n7.1<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n7.5<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n32.0<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n32.4<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
Operating Profit, %<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n9.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n12.2<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n10.8<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n13.2<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0Torsh\u00e4lla, April 27th, 2023.<\/span><\/p>\n

<\/p>\n

This information is such information that Stille AB is obliged to disclose according to the EU\u2019s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on April 27th, 2023, kl. 08.00 (CET).<\/em><\/p>\n

\n

For more information, please contact:<\/span><\/span><\/p>\n

Torbj\u00f6rn Sk\u00f6ld<\/span><\/span><\/strong>
\nCEO and President
\n+46 (0)70 316 63 91 | torbjorn.skold@stille.se<\/span><\/span><\/p>\n<\/div>\n

\n

Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.<\/span><\/span><\/p>\n<\/div>\n